Technology transfer / Localization · GCC · Announced 28 Oct 2025
Local Content and Government Procurement Authority → Boston Oncology
Saudi Arabia's LCGPA signed localisation and knowledge-transfer agreements with Boston Oncology for two biologics, etanercept and adalimumab, at the Global Health Exhibition 2025 in Riyadh.
Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → Boston Oncology (Saudi Arabia)
- Deal type
- Technology transfer / Localization
- Value
- Undisclosed
- Territory
- Saudi Arabia — local manufacturing and knowledge transfer
- Therapeutic area
- Immunology / Inflammation
- Assets
- etanercept; adalimumab
- Announced
- 28 Oct 2025
Our analysis
Why this matters
On 28 October 2025, at the Global Health Exhibition in Riyadh, Saudi Arabia's Local Content and Government Procurement Authority (LCGPA) signed five localisation agreements for medical and pharmaceutical products. Boston Oncology signed two of them: one for the local manufacture of, and knowledge transfer for, etanercept, and one for adalimumab. Both are biologics for chronic inflammatory diseases. The Saudi Press Agency confirmed that the ceremony ended with the etanercept agreement.
No value was given for each agreement. The LCGPA said the five together are expected to add more than SAR 1.2 billion to GDP and create about 500 direct jobs. This entry rests mainly on one detailed source (Al Watan); the SPA release confirms the etanercept agreement but does not name the company.
The full analysis is free to read with a work email on this page.
Source: Al Watan (Saudi Arabia)